TPST - Tempest Therapeutics, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

TPST

TEMPEST THERAPEUTICS, INC.

NASDAQ

$1.06

▼ DOWN 1.85% (-0.02)

KEY STATISTICS

Market Cap$16.94 M

52w High$12.23

52w Low$0.84

Dividend Yield—

Frequency—

P/E-0.18

Volume62.10K

Shares Out.15.98M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Matthew Angel

COMPENSATION 2026

Salary$600,000

Stock Awards$0

Incentive Plan Pay$280,500

All Other Comp.$13,800

Total$1,872,299

ABOUT

SECTOR

Healthcare

WENT PUBLIC

November 12, 2012

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateNov 4, 2026

DayWednesday

Rev. Est.—

NOV

WED

SPLIT RECORD

DATE	TYPE	RATIO
2025-04-09	Reverse	1:13
2021-06-28	Reverse	1:15
2021-06-25	Reverse	1:15
2018-12-10	Reverse	1:15

PRICE

$1.06 ▼ DOWN 1.85% (−$0.02)

OVERLAYS

About Tempest Therapeutics, Inc.

https://www.tempesttx.com ↗

Tempest Therapeutics Inc. is a clinical-stage oncology company developing small molecule therapeutics, including TPST-1495 and TPST-1120 in Phase 1 trials, and exploring immune regulation via TREX-1.

INDUSTRY

Biotechnology

A PRODUCT TEMPEST THERAPEUTICS, INC. IS KNOWN FOR

TPST-2003

Tempest Therapeutics' TPST-2003 is a dual-targeting CAR-T therapy for relapsed/refractory multiple myeloma, showing a 100% response in early trials and progressing toward BLA submission in China.